High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines-Reference-Cited by-同舟云学术

High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines

Published:2016-02-29 Issue:4 Volume:34 Page:419-423
ISSN:1087-0156
Container-title:Nature Biotechnology
language:en
Short-container-title:Nat Biotechnol

Author:

Yu Channing^ORCID,Mannan Aristotle M,Yvone Griselda Metta,Ross Kenneth N,Zhang Yan-Ling,Marton Melissa A,Taylor Bradley R,Crenshaw Andrew,Gould Joshua Z,Tamayo Pablo^ORCID,Weir Barbara A,Tsherniak Aviad^ORCID,Wong Bang,Garraway Levi A,Shamji Alykhan F,Palmer Michelle A,Foley Michael A,Winckler Wendy,Schreiber Stuart L,Kung Andrew L,Golub Todd R

Publisher

Springer Science and Business Media LLC

Subject

Biomedical Engineering,Molecular Medicine,Applied Microbiology and Biotechnology,Bioengineering,Biotechnology

Link

http://www.nature.com/articles/nbt.3460.pdf

Reference26 articles.

1. McDermott, U. et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Natl. Acad. Sci. USA 104, 19936–19941 (2007).

2. Sos, M.L. et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J. Clin. Invest. 119, 1727–1740 (2009).

3. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).

4. Garnett, M.J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570–575 (2012).

5. Sharma, S.V., Haber, D.A. & Settleman, J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat. Rev. Cancer 10, 241–253 (2010).

Cited by 263 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A hierarchical attention network integrating multi-scale relationship for drug response prediction;Information Fusion;2024-10

2. Multi‑omics identification of a signature based on malignant cell-associated ligand–receptor genes for lung adenocarcinoma;BMC Cancer;2024-09-12

3. BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models;Nature Cancer;2024-08-23

4. Research on molecular characteristics of ADME-related genes in kidney renal clear cell carcinoma;Scientific Reports;2024-07-22

5. Latent mitotic vulnerability of AML cells induced by therapeutic agents;2024-07-01